Repligen Co. (NASDAQ:RGEN) Position Increased by LPL Financial LLC

LPL Financial LLC grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 47.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,237 shares of the biotechnology company's stock after buying an additional 10,395 shares during the period. LPL Financial LLC owned 0.06% of Repligen worth $4,873,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in RGEN. Signaturefd LLC lifted its stake in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares during the period. Resources Management Corp CT ADV acquired a new position in Repligen in the 3rd quarter valued at $37,000. Quarry LP boosted its holdings in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 239 shares during the last quarter. UMB Bank n.a. grew its position in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the period. Finally, Global Retirement Partners LLC grew its position in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Up 6.7 %

Shares of NASDAQ RGEN traded up $7.67 during midday trading on Friday, reaching $122.86. 978,190 shares of the company's stock were exchanged, compared to its average volume of 702,002. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52. The business's fifty day moving average price is $143.12 and its two-hundred day moving average price is $146.32. The stock has a market capitalization of $6.90 billion, a PE ratio of -240.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Insider Activity at Repligen

In other news, Director Margaret Pax acquired 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently commented on RGEN. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.